my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
17-10-2007: Servier and NiKem Research Srl announced the signature of a Discovery Research Service Agreement. Under the terms of the agreement NiKem will, in the next 12 months, use its medicinal chemistry experience, and its iterative and parallel chemistry platform, to design and synthesize drug-like kinase inhibitors aimed towards specific, undisclosed targets of interest for Servier. Financial terms of the agreement were not disclosed.
Watchlist
This is where you can add this news to your personal favourites
Galapagos delivers candidate drug in osteoarthritis alliance with Servier
Galapagos NV announced that it has identified the first pre-clinical candidate compound in its osteoarthritis alliance with Servier. The compound inhibits a novel mechanism of action discovered by Galapagos. This achievement triggered an undisclosed milestone payment to Galapagos. In July ... more
Servier and Galapagos initiate strategic alliance for innovative treatments in oncology
Servier and Galapagos NV announced that they have entered into a multi-year strategic alliance to develop new cancer therapies. The alliance builds on a combination of novel Galapagos and Servier targets in oncology. Galapagos will be responsible for the discovery and development of new c ... more
Hybrigenics and Servier announced that they have signed a licence and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics will identify and ... more
NiKem Research Srl and Dualsystems Biotech AG Announce a Strategic Alliance
Dualsystems Biotech and NiKem Research announced the formation of a strategic alliance to jointly offer their respective drug/target profiling and drug discovery services to their clients.The ever increasing complexity and expense of drug discovery requires an excellent understanding of mol ... more
NiKem Research and Chiesi Farmaceutici Extend Research Collaboration
Chiesi Farmaceutici and NiKem Research have announced details of their extended research collaboration within the respiratory therapeutic area. Since 2001 Chiesi and NiKem successfully collaborate on several pre-clinical research projects where NiKem provides design, synthesis, hit validati ... more
NiKem Research Receives Authorization for Rodent Toxicology Studies
NiKem Research announces that it has received on March 29th 2010, from the Italian Ministry of Health (Decree N. 69/2010-B), the authorization to perform acute and sub-chronic toxicology studies (up to 28 days) in all rodent species for preliminary safety evaluation of novel chemical entiti ... more
Based on decades of drug discovery experience and now operating at biotech speed, NiKem Research offers a full range of drug discovery services to the pharmaceutical industry. In addition to its expertise in medicinal chemistry (hit validation, hit to lead and lead optimization, iterative a ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
